Imprimis Pharmaceuticals Receives Institutional Review Board (IRB) Approval for Its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, July 22, 2013 /PRNewswire/ — Imprimis Pharmaceuticals…

ADVERTISEMENT — Advertise With Biotech Networks